This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AKRX Akorn (AKRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Akorn Stock (NASDAQ:AKRX) 30 days 90 days 365 days Advanced Chart Remove Ads Get Akorn alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.09▼$0.3252-Week Range N/AVolume1.19 million shsAverage Volume9.60 million shsMarket Capitalization$3.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAkorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.Read More… Remove Ads Receive AKRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akorn and its competitors with MarketBeat's FREE daily newsletter. Email Address AKRX Stock News HeadlinesAkorn Reaches New 52-Week High (AKRX)May 15, 2023 | thestreet.comCarlin Consumer Health Names Scott Chapman Chief Executive Officer - Business WireOctober 20, 2022 | businesswire.comUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 40-year career. During the presentation, Larry reveals a strategy every trader and investor needs to understand. He calls it “Bitcoin Skimming.”April 4, 2025 | Brownstone Research (Ad)Veterinary Eye Care Market Size to record USD 788.78 Million Growth at a CAGR of 4.65% by 2026, Evolving Opportunities with Bausch Health Co Inc. And Akorn Operating Co. - Technavio - PR NewswireOctober 10, 2022 | prnewswire.comA small fund wagered that Elon Musk would be forced to buy Twitter—and made a killing by betting against the crowd - FortuneOctober 9, 2022 | fortune.comDiuretic Drugs Market to Record a CAGR of 5.44%, Increasing Incidence of Hypertension Among People to Drive Growth - Technavio - Yahoo FinanceSeptember 29, 2022 | finance.yahoo.comMoody's downgrades Akorn to Caa2; revises outlook to stable from positive - Moody'sSeptember 15, 2022 | moodys.comPrestige Consumer (PBH) Brands & E-commerce Strength Bode Well - NasdaqSeptember 2, 2022 | nasdaq.comSee More Headlines AKRX Stock Analysis - Frequently Asked Questions How were Akorn's earnings last quarter? Akorn, Inc. (NASDAQ:AKRX) released its quarterly earnings data on Monday, May, 11th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.45. The firm had revenue of $204.69 million for the quarter, compared to the consensus estimate of $168.90 million. Akorn had a negative net margin of 55.64% and a positive trailing twelve-month return on equity of 8.53%. What other stocks do shareholders of Akorn own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akorn investors own include Bristol-Myers Squibb (BMY), Integrated Device Technology (IDTI), Skechers U.S.A. (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC) and Quantenna Communications (QTNA). Company Calendar Last Earnings5/11/2020Today4/04/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AKRX CIK3116 Webwww.akorn.com Phone847-279-6100FaxN/AEmployees2,227Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-226,770,000.00 Net Margins-55.64% Pretax MarginN/A Return on Equity8.53% Return on Assets1.31% Debt Debt-to-Equity Ratio0.09 Current Ratio0.50 Quick Ratio0.32 Sales & Book Value Annual Sales$682.43 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.19 Book Value$1.86 per share Price / BookN/AMiscellaneous Outstanding Shares133,152,000Free FloatN/AMarket Cap$3.60 million OptionableOptionable Beta0.95 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:AKRX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akorn, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akorn With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.